Blood ClotMIGHTYNCT07363525
Michigan Initial Experience Using Tigertriever for Thrombectomy
An observational study of Blood Clot and Thrombectomy, run by Henry Ford Health System at 1 site in United States.
Trial summary
The purpose of this research study is to collect data about the effectiveness (i.e. how the device works) and safety (how safe it is to use such a device) of the Tigertriever in restoring blood flow by removing thrombus (or blood clot) from a large intracranial vessel (blood vessel in the brain) in patients… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Blood Clot, Thrombectomy, Ischemic Stroke
- What is being tested?
- Mechanical Thrombectomy
- Type of treatment
- Surgery or procedure
- How many people
- 150 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Jan 2026to 31 Dec 2028
- How long will I take part?
- 90 Days
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The registry will include male or female subjects age > 18 who present with LVO and are treated with the Tigertriever as per the approved indication.
Who may be able to join
- Patients admitted with large vessel occlusion (LVO) and treated with the Tigertriever, as per the approved indication.
- Tigertriever was used as the first line treatment in the target vessel.
- A signed informed consent.
- Age ≥ 18.
Who cannot join
- -1. Evidence of acute brain hemorrhage on NCCT or MR at admission. 2. Prior hemorrhage, stroke, thrombolysis, and/or endovascular therapy in the last 3 months.
- 3. pre-stroke disability (pre-stroke mRS ≥ 2).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Henry Ford Hospital
Detroit, Michigan, 48202
Alex B Chebl, MD, 3132070432, achebl1@hfhs.org
Kelly Tundo, KCIACH1@hfhs.org
About this study
The purpose of this research study is to collect data about the effectiveness (i.e. how the device works) and safety (how safe it is to use such a device) of the Tigertriever in restoring blood flow by removing thrombus (or blood clot) from a large intracranial vessel (blood vessel in the brain) in patients experiencing ischemic stroke within 8 hours of symptom onset.
Read the detailed description
You have been asked to take part in a research study because you have recently been admitted for large vessel occlusion (LVO) and are being treated by Tigertriever.
The treatment is a standard of care (SOC), and if you agree to take part in this study, your participation will include an additional study visit after 3 months. Your study visit will take place at Henry Ford Hospital Neurology or respective collaborator.
For some research studies, such as the one you are being asked to join, it is important that you do not learn the results of certain tests. Whether you intend it or not, sometimes learning this information may make you change your actions and behaviors in ways that could impact the outcome of the study.
- Conditions
- Blood Clot, Thrombectomy, Ischemic Stroke
- Being tested
- Mechanical Thrombectomy
- Keywords
- thrombus, Clot, Device, Stroke
- Medical subject headings
- Thrombosis, Ischemic Stroke, Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mechanical ThrombectomyProcedure or surgery
You will be asked to provide medical history, take neurological exams in the form of questionnaires, and provide imaging data.
| Study group | Role | What they receive |
|---|---|---|
| Thrombectomy Treated Patients | Patients are enrolled only if the use of the Tigertreiver is used during surgery. Receives: Procedure: Mechanical Thrombectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Modified Rankin Scale
Percentage of participants with a modified Rankin Scale (mRS) score ≤2
Measured: From enrollment to 90 days post treatment
Primary Effectiveness Endpoint
Percentage of participants with a mTICI Score ≥IIb
Measured: By the end of the thrombectomy procdure.
Primary Effectiveness Endpoint - mTICI
Percentage of participants with a mTICI Score ≥IIb after the first pass
Measured: From time of event to after the first thrombectomy pass.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jan 2026
- Study start15 Jan 2026
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Blood ClotStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 150 participants (estimated)
- Target duration
- 90 Days
Sponsor and investigators
- Lead sponsor
- Henry Ford Health System
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Alex Chebl, Henry Ford Health System
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07363525
- Sponsor's protocol ID
- 18750
- Acronym
- MIGHTY
- Status last verified
- May 2026
- First submitted
- 8 Jan 2026
- Last updated
- 8 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No: De-identified data will only be shared and used for publication.
Study at a glance
From the registry record, last updated by the sponsor on 8 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Michigan Initial Experience Using Tigertriever for Thrombectomy
- ClinicalTrials.gov ID
- NCT07363525
- Acronym / sponsor ID
- MIGHTY / 18750
- Conditions
- Blood Clot, Thrombectomy, Ischemic Stroke
- Keywords
- thrombus, Clot, Device, Stroke
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Henry Ford Health SystemUniversity, hospital or other
- Study start
- 15 Jan 2026 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 23 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this research study is to collect data about the effectiveness (i.e. how the device works) and safety (how safe it is to use such a device) of the Tigertriever in restoring blood flow by removing thrombus (or blood clot) from a large intracranial vessel (blood vessel in the brain) in patients experiencing ischemic stroke within 8 hours of symptom onset.
Detailed description
You have been asked to take part in a research study because you have recently been admitted for large vessel occlusion (LVO) and are being treated by Tigertriever.
The treatment is a standard of care (SOC), and if you agree to take part in this study, your participation will include an additional study visit after 3 months. Your study visit will take place at Henry Ford Hospital Neurology or respective collaborator.
For some research studies, such as the one you are being asked to join, it is important that you do not learn the results of certain tests. Whether you intend it or not, sometimes learning this information may make you change your actions and behaviors in ways that could impact the outcome of the study.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 90 Days
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Thrombectomy Treated Patients | – | Procedure: Mechanical ThrombectomyPatients are enrolled only if the use of the Tigertreiver is used during surgery. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The registry will include male or female subjects age > 18 who present with LVO and are treated with the Tigertriever as per the approved indication.
Key inclusion criteria (4 listed)
- Patients admitted with large vessel occlusion (LVO) and treated with the Tigertriever, as per the approved indication.
- Tigertriever was used as the first line treatment in the target vessel.
- A signed informed consent.
- Age ≥ 18.
Key exclusion criteria (2 listed)
- -1. Evidence of acute brain hemorrhage on NCCT or MR at admission. 2. Prior hemorrhage, stroke, thrombolysis, and/or endovascular therapy in the last 3 months.
- 3. pre-stroke disability (pre-stroke mRS ≥ 2).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mechanical ThrombectomyYou will be asked to provide medical history, take neurological exams in the form of questionnaires, and provide imaging data. | Procedure or surgery | Thrombectomy Treated Patients |
Primary outcome
Modified Rankin Scale
Time frame: From enrollment to 90 days post treatment
Percentage of participants with a modified Rankin Scale (mRS) score ≤2
Primary Effectiveness Endpoint
Time frame: By the end of the thrombectomy procdure.
Percentage of participants with a mTICI Score ≥IIb
Primary Effectiveness Endpoint - mTICI
Time frame: From time of event to after the first thrombectomy pass.
Percentage of participants with a mTICI Score ≥IIb after the first pass
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2026.
- Individual participant dataSharing planned: No. De-identified data will only be shared and used for publication.
Related trials for Blood Clot
Recruiting
Low-dose Colchicine for Thromboprophylaxis After Transcatheter Aortic Valve Replacement
Transcatheter Aortic Valve Replacement, Transcatheter Heart Valve Thrombosis
Not yet recruitingObservational study
A Case-Control Study Revealing Intraocular Microenvironment Characteristics in Patients With Ocular Diseases Based on Multi-Omics Analysis
Age- Related Macular Degeneration, Diabetic Retinopathy
RecruitingObservational study
RevCore for In Stent Thrombosis
In-stent Thrombosis
RecruitingObservational study
National Eye Institute Biorepository for Retinal Diseases
Age-Related Macular Degeneration, Diabetic Retinopathy
RecruitingObservational study
Clinical and Basic Investigations Into Known and Suspected Congenital Disorders of Glycosylation
Congenital Disorders of Glycosylation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Blood Clot and Thrombectomy, run by Henry Ford Health System at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Alex Chebl, MD (313-916-2644, achebl1@hfhs.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Modified Rankin Scale (time frame: From enrollment to 90 days post treatment). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2026.